Fixed-Dose Combination Antidiabetic Therapy: Real-World Factors Associated with Prescribing Choices and Relationship with Patient Satisfaction and Compliance

详细信息    查看全文

• 作者：Mike Benford (1)
  Gary Milligan (1)
  James Pike (1)
  Peter Anderson (1)
  James Piercy (1)
  Steve Fermer (1)
  
• 关键词：compliance ; dipeptidyl peptidase ; 4 inhibitors ; real ; world ; satisfaction ; simplified dosage regimen ; type 2 diabetes
• 刊名：Advances in Therapy
• 出版年：2012
• 出版时间：January 2012
• 年：2012
• 卷：29
• 期：1
• 页码：26-40
• 全文大小：688KB
• 参考文献：1. World Health Organization. Diabetes, Fact sheet No 312. August 2011. Available at: http://www.who.int/mediacentre/factsheets/fs312/en/index.html. Accessed September 20, 2011.
  2. Van Dieren S, Beulens JW, van der Schouw YT, et al. The global burden of diabetes and its complications: an emerging pandemic. Eur J Cardiovasc Prev Rehabil. 2010;17:S3–S8.
  3. Danaei G, Finucane MM, Lu Y, et al. National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 countryyears and 2.7 million participants. Lancet. 2011;378:31-0. CrossRef
  4. Fisher L, Mullan JT, Skaff MM, et al. Predicting diabetes distress in patients with Type 2 diabetes: a longitudinal study. Diabet Med. 2009;26:622-27. CrossRef
  5. Fisher L, Mullan JT, Arean P, et al. Diabetes distress but not clinical depression or depressive symptoms is associated with glycemic control in both crosssectional and longitudinal analyses. Diabetes Care. 2010;33:23-8. CrossRef
  6. Perneger TV, Brancati FL, Whelton PK, et al. Endstage renal disease attributable to diabetes mellitus. Ann Intern Med. 1994;121:912-18.
  7. Stamler J, Vaccaro O, Neaton JD, et al. Diabetes, other risk factors, and 12 year cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care. 1993;16:434-44. CrossRef
  8. International Diabetes Federation. IDF Clinical Guidelines Task Force. Global guideline for type 2 diabetes. Brussels: International Diabetes Federation, 2005. Available at: http://www.idf.org/webdata/docs/IDF%20GGT2D.pdf. Accessed September 20, 2011.
  9. Cook MN, Girman CJ, Stein PP, et al. Initial monotherapy with either metformin or sulphonylureas often fails to achieve or maintain current glycaemic goals in patients with type 2 diabetes in UK primary care. Diabet Med. 2007;24:350-58. CrossRef
  10. Huppertz E, Piper L, Klotsche J, et al. Diabetes mellitus in German primary care: quality of glycaemic control and subpopulations not well controlled -results of the DETECT study. Exp Clin Endocrinol Diabetes. 2009;117:6-4. CrossRef
  11. Jenssen TG, Tonstad S, Claudi T, et al. The gap between guidelines and practice in the treatment of type 2 diabetes. A nationwide survey in Norway. Diabetes Res Clin Pract. 2008;80:314-20. CrossRef
  12. Ratsep A, Kalda R, Lember M. Meeting targets in type 2 diabetes care contributing to good glycaemic control. A cross-sectional study from a primary care setting in Estonia. Eur J Gen Pract. 2010;16:85-1. CrossRef
  13. Nathan DM, Buse JB, Davidson MB, et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2009;32:193-03. CrossRef
  14. Ryden L, Standl E, Bartnik M, et al. Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). Eur Heart J. 2007;28:88-36. CrossRef
  15. Alvarez Guisasola F, Tofe Povedano S, Krishnarajah G, et al. Hypoglycaemic symptoms, treatment satisfaction, adherence and their association with glycaemic goal in patients with type 2 diabetes mellitus: findings from the Real-Life Effectiveness and Care Patterns of Diabetes Management (RECAP-DM) study. Diabetes Obes Metab. 2008;10:25-2. CrossRef
  16. Handelsman Y, Jellinger PS. Overcoming obstacles in risk factor management in type 2 diabetes mellitus. J Clin Hypertens (Greenwich). 2011;13:613-20. CrossRef
  17. Hanko B, Kazmer M, Mumli P, et al. Self-reported medication and lifestyle adherence in Hungarian patients with type 2 diabetes. Pharm World Sci. 2007;29:58-6. CrossRef
  18. Schmittdiel JA, Uratsu CS, Karter AJ, et al. Why don’t diabetes patients achieve recommended risk factor targets? Poor adherence versus lack of treatment intensification. J Gen Intern Med. 2008;23:588-94. CrossRef
  19. Horne R, Weinman J, Barber N, et al. Concordance, adherence and compliance in medicine taking. Report for the National Coordinating Centre for NHS Service Delivery and Organisation R&D (NCCSDO). 2005. Available at: http://www.sdo.nihr.ac.uk/files/project/SDO_ES_08-1412-076_V01.pdf. Accessed November 23, 2011.
  20. Biderman A, Noff E, Harris SB, et al. Treatment satisfaction of diabetic patients: what are the contributing factors? Fam Pract. 2009;26:102-08. CrossRef
  21. Benhalima K, Wilmot E, Khunti K, et al. Type 2 diabetes in younger adults: clinical characteristics, diabetes-related complications and management of risk factors. Prim Care Diabetes. 2011;5:57-2. CrossRef
  22. Yurgin NR, Boye KS, Dilla T, et al. Physician and patients management of type 2 diabetes and factors related to glycemic control in Spain. Patient Prefer Adherence. 2008;2:87-5.
  23. Vemeire E, Hearnshaw H, Van Royen P, et al. Patient adherence to treatment: three decades of research. A comprehensive review. J Clin Pharm Ther. 2001;26:331-42. CrossRef
  24. Donnan PT, MacDonald TM, Morris AD. Adherence to prescribed oral hypoglycaemic medication in a population of patients with type 2 diabetes: a retrospective cohort study. Diabet Med. 2002;19:279-84. CrossRef
  25. Anderson P, Benford M, Harris N, et al. Realworld physician and patient behaviour across countries: disease-specific programmes -a means to understand. Curr Med Res Opin. 2008;24:3063-072. CrossRef
  26. European Pharmaceutical Market Research, Association Code of Conduct for International, Healthcare Market Research. Available at:www.ephmra.org/professional-standards.aspx. Accessed September 10, 2010.
  27. Bradley C. The Diabetes Treatment Satisfaction Questionnaire: DTSQ. In: Bradley C, ed. Handbook of Psychology and Diabetes: a Guide to Psychological Measurement in Diabetes Research and Practice. Chur: Harwood Academic Publishers; 1994:111-32.
  28. Hutchins V, Zhang B, Fleurence RL, et al. A systematic review of adherence, treatment satisfaction and costs, in fixed-dose combination regimens in type 2 diabetes. Curr Med Res Opin. 2011;27:1157-168. CrossRef
  
• 作者单位：Mike Benford (1)
  Gary Milligan (1)
  James Pike (1)
  Peter Anderson (1)
  James Piercy (1)
  Steve Fermer (1)
  
  1. Steve Fermer Adelphi Real World, Adelphi Mill, Bollington, UK
  

文摘

Introduction Compliance with antidiabetic therapy has the potential to impact on the risk for complications by an effect on glycemic control. Fixed-dose combinations (FDCs) offer a simplified dosing regimen that may improve patient compliance. We undertook a retrospective database analysis to understand the real-world association between FDCs, treatment practices, glycated hemoglobin (HbA1c) levels, and patient perspectives in type 2 diabetes. Methods Data were drawn from the Adelphi Diabetes Disease Specific Programme (DSP), a multicenter, patient recordbased market research study of primary care physicians and diabetologists/endocrinologists in Europe. The study is based on physician interviews, completion of detailed patient record forms by physicians, and a self-completion questionnaire by patients. Regression analyses were used to identify factors associated with (1) physician-reported dipeptidyl peptidase-4 inhibitor (DPP-4)/metformin FDC prescribing in dual or triple therapy regimens; (2) HbA1c of patients prescribed a DPP-4 FDC alone versus free-form DPP-4 plus metformin dual therapy regimens; and (3) differences between patients prescribed any oral antidiabetic therapy (OAD) FDC therapy (alone or in combination with one other OAD) versus those prescribed dual or triple OAD free-form combination therapy. Results Physician-reported data were available for 5891 patients (mean age 61.5 years, 43% female, mean duration since diagnosis 5.7 years). Factors associated with DPP-4 FDC usage included physicians-reason for choice being “improves patient compliance.-The relative mean % HbA1c level associated with being on a DPP-4 FDC rather than free-form independent of the physician perception of patient compliance was 0.25 lower (CI ?.40 to ?.09). When physician-perceived patient compliance was described as “fairly compliant-rather than “poorly compliant-or “not at all compliant,-the relative mean % HbA1c level was 0.42 lower (CI ?.67 to ?.18). Similarly, being perceived as “fully compliant-rather than “fairly compliant-was associated with a relative mean % HbA1c level that was 0.17 lower (CI ?.31 to ?.02). A significant predictor for the current regimen being any FDC (alone or in combination with one other OAD) regimen was patients-satisfaction with treatment (odds ratio 1.32; 95% CI 1.10 to 1.58; P=0.003). Conclusions These results suggest that DPP-4 FDC prescribing is considered to be a positive prescribing choice to improve compliance and that choice is associated with improved glycemic control. From the patient’s perspective, the decision to prescribe an FDC is associated with improved satisfaction with treatment.